HealthEquity’s HSA Growth And Reaffirmed Outlook Might Change The Case For Investing In HQY

Simply Wall St.03-01 09:26

In late February 2026, HealthEquity reported solid year-over-year growth in health savings accounts and assets, while reaffirming its outlook for fiscal 2026 and 2027, signaling continued confidence ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616427228?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6034000-choice1-main-header/1585187559063","is_english":true,"pubTime":"2026-03-01 09:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616427228","market":"sg","top_or_hot":-1,"title":"HealthEquity’s HSA Growth And Reaffirmed Outlook Might Change The Case For Investing In HQY","media":"Simply Wall St.","content":"<div>\n<p>In late February 2026, HealthEquity reported solid year-over-year growth in health savings accounts and assets, while reaffirming its outlook for fiscal 2026 and 2027, signaling continued confidence ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/healthequitys-hsa-growth-and-reaffirmed-outlook-might-change\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HealthEquity’s HSA Growth And Reaffirmed Outlook Might Change The Case For Investing In HQY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealthEquity’s HSA Growth And Reaffirmed Outlook Might Change The Case For Investing In HQY\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-01 09:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/healthequitys-hsa-growth-and-reaffirmed-outlook-might-change><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late February 2026, HealthEquity reported solid year-over-year growth in health savings accounts and assets, while reaffirming its outlook for fiscal 2026 and 2027, signaling continued confidence ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/healthequitys-hsa-growth-and-reaffirmed-outlook-might-change\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/healthequitys-hsa-growth-and-reaffirmed-outlook-might-change","article_id":"2616427228","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6034000-choice1-main-header/1585187559063"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-hqy/healthequity/news/healthequitys-hsa-growth-and-reaffirmed-outlook-might-change","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616427228","pubTimestamp":1772328360,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late February 2026, HealthEquity reported solid year-over-year growth in health savings accounts and assets, while reaffirming its outlook for fiscal 2026 and 2027, signaling continued confidence in its business trajectory.\nThis combination of expanding HSA activity and maintained guidance underlines how HealthEquity is benefiting from growing demand for tax-advantaged healthcare spending and savings solutions.\nNext, we'll examine how reaffirmed multi-year guidance may influence...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","HQY":"HealthEquity","BK4154":"管理型保健护理","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC"},"translate_title":"HealthEquity的HSA增长和重申的前景可能会改变投资HQY的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HQY":1.5},"content_text":"In late February 2026, HealthEquity reported solid year-over-year growth in health savings accounts and assets, while reaffirming its outlook for fiscal 2026 and 2027, signaling continued confidence in its business trajectory. This combination of expanding HSA activity and maintained guidance underlines how HealthEquity is benefiting from growing demand for tax-advantaged healthcare spending and savings solutions. Next, we'll examine how reaffirmed multi-year guidance may influence HealthEquity's investment narrative around future HSA growth and earnings power. Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementHealthEquity Investment Narrative RecapTo own HealthEquity, you need to believe HSAs remain a core tool for tax-advantaged healthcare spending and that the company can keep deepening relationships with employers and members. The latest update of solid HSA account and asset growth, alongside reaffirmed fiscal 2026 and 2027 guidance, supports the near term catalyst of continued product adoption, while not materially changing the key risk that earnings are still sensitive to interest income on custodial cash if rates weaken. The most relevant recent announcement is HealthEquity’s reaffirmed multi year revenue outlook of US$1.302 billion to US$1.312 billion for fiscal 2026 and US$1.38 billion to US$1.41 billion for fiscal 2027, which frames this HSA growth data in the context of a scaling, diversified fee and yield model. For investors, the question is how this plays against the risk that lower interest rates could compress margins just as guidance points higher. Yet behind this reassuring guidance, there is a key risk tied to interest income that investors should be aware of... Read the full narrative on HealthEquity (it's free!)HealthEquity's narrative projects $1.6 billion revenue and $325.3 million earnings by 2028. This requires 7.9% yearly revenue growth and about a $179.5 million earnings increase from $145.8 million today.Uncover how HealthEquity's forecasts yield a $114.44 fair value, a 50% upside to its current price.Exploring Other PerspectivesHQY 1-Year Stock Price Chart Three members of the Simply Wall St Community currently see HealthEquity’s fair value between US$97.01 and US$168.88, highlighting sharply different expectations. Against that backdrop, the reaffirmed multi year guidance and reliance on interest income give you several angles to compare before deciding which view on the company’s performance you find more compelling.Explore 3 other fair value estimates on HealthEquity - why the stock might be worth over 2x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your HealthEquity research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free HealthEquity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate HealthEquity's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Uncover the next big thing with 31 elite penny stocks that balance risk and reward.Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.Outshine the giants: these 22 early-stage AI stocks could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HealthEquity might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616427228","isCrawlerRequest":true}